医学临床研究
   May. 11, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2021, Vol. 38 Issue (10): 1490-1492    DOI: 10.3969/j.issn.1671-7171.2021.10.014
Original Article Current Issue | Archive | Adv Search |
Efficacy and Safety of Quetiapine Joint Midazolam in the Treatment of Alzheimer's Disease with Sleep Disturbance
QIU Zheng, HE Bi- hua, LIN Li
Department of Neurology, Third People's Hospital of Hubei Province, Wuhan Hubei 430033
Download: PDF (1155 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To explore the more effective and safe way of quetiapine combined with midazolam in the treatment of Alzheimer's disease with sleep disturbance. 【Methods】A total of 127 patients with AD and sleep dysfunction were randomly divided into the observation group (n+65) and the control group (n=62). Patients in control group received quetiapine alone, while quetiapine plus midazolam were treated in the observation group. To Clinical efficacy and adverse effect between two groups were compared. 【Results】After 4 weeks of treatment, the total effective rate in the observation group was 96.92% (63/65), which was significantly higher than 80.65% (50/62) in the control group, and the difference was statistically significant (χ2=8.57, P<0.05). After 8 weeks of treatment, the total effective rate of the observation group was 100.00% (65/65), which was significantly higher than 87.10% (54/62) of the control group, and the difference was statistically significant (χ2=8.95, P<0.05). Before treatment, there were no statistically significant differences in the PSQI scores of sleep quality, time to fall asleep, daytime function, sleep disorder, sleep time, sleeping drugs, and total scores between the two groups of patients (all P>0.05). After 4 weeks and 8 weeks of treatment, the observation group's PSQI scores for sleep quality, time to fall asleep, daytime function, sleep time, sleeping drugs and other scores and total scores were significantly lower than those of the control group; And the differences were statistically significant (both P<0.05). However, there was no statistically significant difference in sleep disorder scores between the two groups (P>0.05). The total incidence of adverse reactions in the observation group was 3.07% (2/65), which was significantly lower than 14.52% (9/62) in the control group, and the difference was statistically significant (χ2=5.249, P=0.028).【Conclusion】Quetiapine combined with midazolam in the treatment of Alzheimer's disease with sleep disturbance was more effective and safer than singular quetiapine treatment and it was worth of application.
Key wordsAlzheimer Disease/CO      Sleep Initiation and Maintenance Disorders/CO      Quetiapine Fumarate/TU     
Received: 07 May 2021     
PACS:  R742  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
QIU Zheng
HE Bi- hua
LIN Li
Cite this article:   
QIU Zheng,HE Bi- hua,LIN Li. Efficacy and Safety of Quetiapine Joint Midazolam in the Treatment of Alzheimer's Disease with Sleep Disturbance[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(10): 1490-1492.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.10.014     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I10/1490
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech